02.03.16
Gilead
4Q Revenues: $8.5 billion (+16%)
4Q Earnings: $4.7 billion (+34%)
FY Revenues: $32.6 billion (+31%)
FY Earnings: $18.1 billion (+50%)
Comments: Growth in the quarter was driven by Harvoni with sales of $3.3 billion, up 59%, and partially offset by Sovaldi sales ($1.5 billion, down 11%). Antiviral product sales, which include products for HIV and liver diseases, were $7.9 billion in the quarter, up 18%, primarily as a result of the launch of HCV products in Japan and continued launches across Europe, partially offset by lower sales of HCV products in the U.S. Truvada sales were $936 million in the quarter, up 4%. Atripla sales were $800 million, down 14%. Stribild sales were $511 million, up 33%. Complera / Eviplera sales were $380 million, up 9%. Viread sales were $306 million, down 2%. Letairis, Ranexa and AmBisome sales totaled $523 million in the quarter, up 5%.
4Q Revenues: $8.5 billion (+16%)
4Q Earnings: $4.7 billion (+34%)
FY Revenues: $32.6 billion (+31%)
FY Earnings: $18.1 billion (+50%)
Comments: Growth in the quarter was driven by Harvoni with sales of $3.3 billion, up 59%, and partially offset by Sovaldi sales ($1.5 billion, down 11%). Antiviral product sales, which include products for HIV and liver diseases, were $7.9 billion in the quarter, up 18%, primarily as a result of the launch of HCV products in Japan and continued launches across Europe, partially offset by lower sales of HCV products in the U.S. Truvada sales were $936 million in the quarter, up 4%. Atripla sales were $800 million, down 14%. Stribild sales were $511 million, up 33%. Complera / Eviplera sales were $380 million, up 9%. Viread sales were $306 million, down 2%. Letairis, Ranexa and AmBisome sales totaled $523 million in the quarter, up 5%.
